Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules
Open Access
- 31 March 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (7), 2167-2175
- https://doi.org/10.1158/1078-0432.ccr-09-2236
Abstract
Purpose: Voreloxin, a novel replication-dependent DNA-damaging agent, intercalates DNA and inhibits topoisomerase II. Voreloxin induces site-selective DNA double-strand breaks and apoptosis. We report the phase 1 experience of voreloxin in patients with relapsed/refractory solid tumors, including dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics, and clinical activity.Keywords
This publication has 13 references indexed in Scilit:
- Abstract C226: Clinical evidence of mechanism-based activity in voreloxin-treated AML patientsMolecular Cancer Therapeutics, 2009
- Metabolism of (+)-1,4-Dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acid (Voreloxin; Formerly SNS-595), a Novel Replication-Dependent DNA-Damaging AgentDrug Metabolism and Disposition, 2008
- Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor modelsCancer Chemotherapy and Pharmacology, 2008
- Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621Journal of Clinical Oncology, 2004
- The Quinolone Family: From Antibacterial to Anticancer AgentsCurrent Medicinal Chemistry - Anti-Cancer Agents, 2003
- Use of CA-125 to Assess Response to New Agents in Ovarian Cancer TrialsJournal of Clinical Oncology, 2003
- Delineating the Contribution of Secretory Transporters in the Efflux of Etoposide Using Madin-Darby Canine Kidney (MDCK) Cells Overexpressing P-Glycoprotein (Pgp), Multidrug Resistance-Associated Protein (MRP1), and Canalicular Multispecific Organic Anion Transporter (cMOAT)Drug Metabolism and Disposition, 2002
- Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory PropertiesJournal of Clinical Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Structural Insight into a Quinolone-Topoisomerase II-DNA ComplexPublished by Elsevier BV ,1999